Payment overview · 2025
General Payments
$415.07
22 reported records · 6 companies
Healthcare provider profile · identity verified
Arkadiy Shusterman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1316992928
Verified facts
What the public records show
CMS Open Payments records show Arkadiy Shusterman, DO received $415.07 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Zenpep by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $212.58 | 51.2% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.96 | 17.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.69 | 15.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.99 | 6.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.22 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.63 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.07 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $212.58 | 14 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $183.62 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.96 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $63.69 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 82 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 227 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
227 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 12 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 680 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 59 |
| Metformin Hcl | Metformin Hcl | 345 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 43 |
| Dexlansoprazole Dr | Dexlansoprazole | 284 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 256 | 45 |
| Linzess | Linaclotide | 227 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 190 | 20 |
| Omeprazole | Omeprazole | 183 | 27 |
| Losartan Potassium | Losartan Potassium | 180 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 21 |
| Alendronate Sodium | Alendronate Sodium | 151 | 18 |
| Furosemide | Furosemide | 149 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 23 |
| Simvastatin | Simvastatin | 144 | 20 |
| Clonidine Hcl | Clonidine Hcl | 130 | 22 |
| Allopurinol | Allopurinol | 128 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 128 | 17 |
| Meloxicam | Meloxicam | 127 | 23 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 123 | 16 |
| Carvedilol | Carvedilol | 121 | 15 |
| Synthroid | Levothyroxine Sodium | 121 | 12 |
| Gabapentin | Gabapentin | 116 | 18 |
| Vascepa | Icosapent Ethyl | 115 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 109 | 12 |
| Lisinopril | Lisinopril | 107 | 16 |
| Famotidine | Famotidine | 105 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 104 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 103 | 11 |
| Jardiance | Empagliflozin | 101 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 99 | 16 |
| Myrbetriq | Mirabegron | 96 | 13 |
| Eliquis | Apixaban | 91 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | suppressed |
| Creon | Lipase/Protease/Amylase | 82 | 17 |
| Januvia | Sitagliptin Phosphate | 80 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | suppressed |
| Nifedipine Er | Nifedipine | 70 | 11 |
| Dutasteride | Dutasteride | 69 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 67 | suppressed |
| Rybelsus | Semaglutide | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | suppressed |
| Atenolol | Atenolol | 63 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 62 | suppressed |
| Glimepiride | Glimepiride | 59 | suppressed |
| Tradjenta | Linagliptin | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Azithromycin | Azithromycin | 56 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Ranolazine Er | Ranolazine | 46 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Ztlido | Lidocaine | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Bystolic | Nebivolol Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Dexilant | Dexlansoprazole | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Exelon | Rivastigmine | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Nisoldipine | Nisoldipine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rapaflo | Silodosin | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Avodart | Dutasteride | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Plavix | Clopidogrel Bisulfate | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Risperdal | Risperidone | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.07 · 22 records | ABBVIE INC. | CREON, GEMTESA, LINZESS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, ZAVZPRET, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error